Cost and insurance coverage issues significantly hinder PrEP uptake, especially among those with delayed or non-pickup of prescriptions. Transgender individuals face lower PrEP adoption rates compared ...

Identifying populations at an increased risk for HIV and preventing outbreaks remain a challenge, but researchers are using tracking technology to find these at-risk individuals and provide treatment, ...

The first shipment of Lenacapavir, a long-acting injectable that prevents HIV with two shots a year, arrived in South Africa ...

Between 1995 and 2023, diagnoses of hepatitis C infection increased among HIV-positive men who have sex with men with no history of injection drug use, particularly during the era of highly active ...

Oral HPV prevalence is higher in HIV-positive mother-child pairs, with diverse high- and low-risk subtypes identified. HPV-related cancers are more prevalent in HIV-positive individuals, especially in ...

Twice-yearly lenacapavir (Sunlenca) substantially reduced HIV infection when used for preexposure prophylaxis (PrEP) in cisgender men and transgender or gender-nonbinary persons in the pivotal PURPOSE ...

HIV outbreaks like those in Maine and West Virginia don't emerge because people use needles. They emerge when people share ...

The incidence of skin diseases in people with HIV has declined significantly over the past decade, but some patient groups remain at a higher risk, particularly for cutaneous malignancies (CM), ...

He warned against diversion or commercialisation of the medication, stressing that it was strictly for public health use.